Feterl, Marshall, Govan, Brenda, Engler, Cathy, Norton, Robert, and Ketheesan, Natkunam (2006) Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model. International Journal of Antimicrobial Agents, 28 (5). pp. 460-464.

PDF (Published version) Restricted to Repository staff only

 

8

1

Abstract

Burkholderia pseudomallei is the causative agent of melioidosis. Standard therapy includes ceftazidime alone or in combination with co-trimoxazole. Tigecycline, a novel agent, has displayed activity against B. pseudomallei. We evaluated the in vivo efficacy of tigecycline using a murine model of melioidosis. Mice were infected with either a high or low virulence B. pseudomallei isolate followed by administration of antibiotics alone or in combination (tigecycline, ceftazidime, tigecycline plus ceftazidime) for 7 days. Bacterial loads were assessed up to 7 days and survival was determined up to 7 days post infection. Tigecycline in combination with ceftazidime was the most effective and conferred the lowest mortality, suggesting the use of this new agent in B. pseudomallei infection.

Actions (Repository Staff Only)

Item Control Page